P&T Motion History
Long Acting Opioid

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision

buprenorphine transdermal film
fentanyl transdermal film
hydrocodone bitartrate
  • **Vantrela ER***
hydromorphone
levorphanol
methadone
morphine
  • MorphaBond®*
  • **Arymo ER***
morphine sulfate/ naltrexone HCL
oxycodone
oxycodone HCL/ naloxone HCL
oxymorphone
tapentadol
	After considering the updated evidence of harms, efficacy and special populations for the treatment of non-cancer pain, I move that buprenorphine transdermal film**,** transdermal fentanyl, hydrocodone bitartrate, oxycodone/ naloxone HCL, tapentadol, oral oxycodone ER, morphine ER, methadone, levorphanol, and oxymorphone are efficacious when used appropriately and have similar adverse effects. There should be more than one oral preferred drug in the long acting opioid class.
	
	Motion: Johnson
	2nd: Flatebo
		December 20, 2017	Yes
			Johnson
			Sanderson
				No	Passed unanimous

buprenorphine transdermal film fentanyl transdermal film hydrocodone bitartrate hydromorphone levorphanol	After considering the updated evidence of safety, efficacy and special populations for the treatment of non-cancer pain, I move that buprenorphine transdermal film**,** transdermal fentanyl, hydrocodone bitartrate, oxycodone/ naloxone HCL, tapentadol, oral oxycodone ER, morphine ER, methadone, levorphanol, and oxymorphone are safe and	December 21, 2016	Yes Johnson Bowman	Yes Harvey Rowe	Passed unanimous

*Not eligible for inclusion on the PDL

Grey = not reviewed, cannot be included in motion

Bold=new this update

methadone morphine • **MorphaBond®*** morphine sulfate/ naltrexone HCL oxycodone oxycodone HCL/ naloxone HCL oxymorphone tapentadol	efficacious when used appropriately and have similar adverse effects. There should be more than one oral preferred drug in the long acting opioid class.				

*Not eligible for inclusion on the PDL
Grey = not reviewed, cannot be included in motion
Bold=new this update

12/21/2017